



July 2, 2021

**BSE Limited** 

Code: 532321

1<sup>st</sup> Floor, P J Towers,

Dalal Street,

Mumbai-400001

National Stock Exchange of India Limited

Code: Cadilahc

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 2, 2021 titled "Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets".

The contents of the press release give full details.

AHMEDABAD

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED

DHAVAL N. SÓNI

**COMPANY SECRETARY** 

Encl.: As above



ss Release Press Release
Press Release

Press Rele

Press Release

Press Release

Press Release

## Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Ahmedabad, India, 2 July, 2021

Zydus Cadila has received final approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg (US RLD: Truvada). The drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in one's body so that the immune system can work better.

The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

## **About Zydus**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

\*\*\*

Phone: +91-079-71800000, +91-079-48040000 www.zyduscadila.com

CIN: L24230GJ1995PLC025878